세계의 폐색전증 시장 보고서(2025년)

A pulmonary embolism is a condition characterized by the blockage of the pulmonary artery, which carries blood from the heart to the lungs. This blockage typically results from a blood clot that has traveled from another part of the body, most commonly the legs. Symptoms of a pulmonary embolism can vary, ranging from sudden shortness of breath to chest pain, coughing up blood or bloody mucus, and other signs, with the severity depending on the size and location of the clot.

The primary types of treatment for pulmonary embolism encompass medications, mechanical devices, surgery, and other therapeutic interventions. Medications are substances used for medical purposes to treat, manage, prevent, or alleviate various medical conditions and illnesses. Diagnosis of a pulmonary embolism involves various methods, including chest X-rays, electrocardiograms (ECGs), magnetic resonance imaging (MRI), computed tomography scans, pulmonary angiography, venography, venous ultrasound, D-Dimer tests, and others. Symptoms may include shortness of breath, chest pain, cough, irregular heartbeat, dizziness, fever, cyanosis, and more. Medications for treating pulmonary embolism are primarily distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other relevant channels. Healthcare providers in hospitals, specialty clinics, homecare settings, and other medical facilities typically manage the treatment of pulmonary embolism.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The pulmonary embolism market research report is one of a series of new reports from The Business Research Company that provides pulmonary embolism market statistics, including pulmonary embolism industry global market size, regional shares, competitors with a pulmonary embolism market share, detailed pulmonary embolism market segments, market trends and opportunities and any further data you may need to thrive in the pulmonary embolism industry. This pulmonary embolism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pulmonary embolism market size has grown rapidly in recent years. It will grow from $2.03 billion in 2024 to $2.26 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to anticoagulant therapies, research and clinical trials, pulmonary embolism awareness, vte prophylaxis.

The pulmonary embolism market size is expected to see rapid growth in the next few years. It will grow to $3.62 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to targeted therapies, telemedicine and remote monitoring, health equity initiatives, global health initiatives. Major trends in the forecast period include artificial intelligence in diagnosis, novel anticoagulants, pulmonary embolism response teams, patient-centered care.

The forecast of 12.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt emergency care by increasing costs for mechanical thrombectomy devices and D-dimer test kits imported from Japan and Belgium, potentially delaying life-saving interventions and raising cardiology department expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The burgeoning prevalence of blood clots is anticipated to be a driving force behind the growth of the pulmonary embolism market in the foreseeable future. Blood clots, medically referred to as thrombi, manifest as gel-like or semi-solid masses within blood vessels. The presence of blood clots escalates the risk of pulmonary embolism by impeding the natural flow of blood to the lungs, causing a blockage. These clots are typically observed in the deep veins of the legs, significantly increasing the likelihood of pulmonary embolism. As an illustration, a Gavi, the Vaccine Alliance article from April 2022 reported a thirty-three-fold surge in the potential occurrence of life-threatening lung clots and a five-fold increase in deep vein thrombosis risk within thirty days after COVID-19 exposure. Consequently, the escalating prevalence of blood clots is a key driver for the growth of the pulmonary embolism market.

The growing prevalence of cancer is expected to drive the growth of the pulmonary embolism market. Cancer refers to a group of diseases marked by the uncontrolled and abnormal growth of cells in the body. The rising incidence of cancer increases the risk of blood clots, such as pulmonary embolism, among cancer patients, leading to higher demand for diagnostics and treatments, including specialized medications. For example, in January 2024, the American Cancer Society, a US-based nonprofit organization, reported that the number of cancer cases rose to 2,001,140 in 2024, up from 1,958,310 in 2023, reflecting an increase of 2.19%. As a result, the increasing prevalence of cancer is driving the expansion of the pulmonary embolism market.

Prominent companies operating in the pulmonary embolism market are dedicated to introducing cutting-edge products such as the Triever16 Curve catheter and the RevCore thrombectomy catheter to maintain a competitive edge. As of June 2023, Inari Medical Inc., a US-based medical device company, has launched the Triever16 Curve catheter and the RevCore thrombectomy catheter. The innovative Triever16 Curve catheter is specially designed for peripheral thrombectomy and pulmonary embolism procedures. Its high trackability and pre-shaped curve facilitate focused aspiration. Moreover, the catheter's unique design offers easy access to larger and more powerful 20F or 24F catheters. On the other hand, the RevCore thrombectomy catheter has been developed for the treatment of venous in-stent thrombosis. This mechanical thrombectomy device utilizes a nitinol basket for capturing and removing blood clots, enhancing the safety and efficacy of pulmonary embolism procedures.

In February 2022, Boston Scientific International, a U.S.-based medical device company, acquired Baylis Medical Company Inc. for $1.75 billion. This acquisition strengthens Boston Scientific's portfolio by enhancing its offerings in structural heart disease and electrophysiology, including advanced transseptal access solutions. Baylis Medical Company Inc., a Canada-based medical device company, specializes in pulmonary embolism interventional tools.

Major companies operating in the pulmonary embolism market are Pfizer Inc., Johnson and Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co.Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, GSK PLC, Abbott Laboratories, AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Mitsubishi Tanabe Pharma Corporation, Genentech Inc., Hikma Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Nippon Shinyaku Co. Ltd., Penumbra Inc., Fresenius Kabi AG, Inari Medical Inc., AngioDynamics Inc., Otsuka Pharmaceutical Co. Ltd.

North America was the largest region in the pulmonary embolism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary embolism report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pulmonary embolism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The pulmonary embolism market consists of revenues earned by entities by providing services such as medical management, thrombolytic therapy, monitoring and oxygen therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The pulmonary embolism market also includes sales of diagnostic imaging equipment, oxygen delivery devices, interventional devices, medical alert systems and pulse oximeters. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pulmonary Embolism Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pulmonary embolism market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pulmonary embolism ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pulmonary embolism market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Medications; Mechanical Devices; Other Treatments
• 2) By Diagnosis: Chest X-Ray; Electrocardiogram (ECG); Magnetic Resonance Imaging (MRI); Computed Tomography Scan; Pulmonary Angiography; Venography; Venous Ultrasound; D-Dimer Test; Other Diagnosis
• 3) By Symptoms: Shortness Of Breath; Chest Pain; Cough; Irregular Heartbeat; Dizziness; Fever; Cyanosis; Other Symptoms
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• 5) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Subsegments:
• 1) By Medications: Anticoagulants; Thrombolytics
• 2) By Mechanical Devices: Inferior Vena Cava (IVC) Filters; Catheter-Assisted Thrombectomy
• 3) By Other Treatments: Surgical Embolectomy; Supportive Care
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson Private Limited; F. Hoffmann-La Roche Ltd.; Merck And Co.Inc.; Novartis AG; Bayer AG; Sanofi S.A.; Bristol Myers Squibb Company; GSK plc; Abbott Laboratories; AstraZeneca plc; Medtronic plc; Eli Lilly and Company; Gilead Sciences Inc.; Baxter International Inc.; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; Mylan N.V.; Daiichi Sankyo Co. Ltd.; Boehringer Ingelheim International GmbH; Mitsubishi Tanabe Pharma Corporation; Genentech Inc.; Hikma Pharmaceuticals plc; Aspen Pharmacare Holdings Limited; Nippon Shinyaku Co. Ltd.; Penumbra Inc.; Fresenius Kabi AG; Inari Medical Inc.; AngioDynamics Inc.; Otsuka Pharmaceutical Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pulmonary Embolism Market Characteristics

3. Pulmonary Embolism Market Trends And Strategies

4. Pulmonary Embolism Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Pulmonary Embolism Growth Analysis And Strategic Analysis Framework

• 5.1. Global Pulmonary Embolism PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Pulmonary Embolism Market Growth Rate Analysis
• 5.4. Global Pulmonary Embolism Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Pulmonary Embolism Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Pulmonary Embolism Total Addressable Market (TAM)

6. Pulmonary Embolism Market Segmentation

• 6.1. Global Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medications
• Mechanical Devices
• Other Treatments
• 6.2. Global Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chest X-Ray
• Electrocardiogram (ECG)
• Magnetic Resonance Imaging (MRI)
• Computed Tomography Scan
• Pulmonary Angiography
• Venography
• Venous Ultrasound
• D-Dimer Test
• Other Diagnosis
• 6.3. Global Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Shortness Of Breath
• Chest Pain
• Cough
• Irregular Heartbeat
• Dizziness
• Fever
• Cyanosis
• Other Symptoms
• 6.4. Global Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 6.5. Global Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users
• 6.6. Global Pulmonary Embolism Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anticoagulants
• Thrombolytics
• 6.7. Global Pulmonary Embolism Market, Sub-Segmentation Of Mechanical Devices, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inferior Vena Cava (IVC) Filters
• Catheter-Assisted Thrombectomy
• 6.8. Global Pulmonary Embolism Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgical Embolectomy
• Supportive Care

7. Pulmonary Embolism Market Regional And Country Analysis

• 7.1. Global Pulmonary Embolism Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Pulmonary Embolism Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pulmonary Embolism Market

• 8.1. Asia-Pacific Pulmonary Embolism Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pulmonary Embolism Market

• 9.1. China Pulmonary Embolism Market Overview
• 9.2. China Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pulmonary Embolism Market

• 10.1. India Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pulmonary Embolism Market

• 11.1. Japan Pulmonary Embolism Market Overview
• 11.2. Japan Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pulmonary Embolism Market

• 12.1. Australia Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pulmonary Embolism Market

• 13.1. Indonesia Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pulmonary Embolism Market

• 14.1. South Korea Pulmonary Embolism Market Overview
• 14.2. South Korea Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pulmonary Embolism Market

• 15.1. Western Europe Pulmonary Embolism Market Overview
• 15.2. Western Europe Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pulmonary Embolism Market

• 16.1. UK Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pulmonary Embolism Market

• 17.1. Germany Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pulmonary Embolism Market

• 18.1. France Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pulmonary Embolism Market

• 19.1. Italy Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pulmonary Embolism Market

• 20.1. Spain Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pulmonary Embolism Market

• 21.1. Eastern Europe Pulmonary Embolism Market Overview
• 21.2. Eastern Europe Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pulmonary Embolism Market

• 22.1. Russia Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pulmonary Embolism Market

• 23.1. North America Pulmonary Embolism Market Overview
• 23.2. North America Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pulmonary Embolism Market

• 24.1. USA Pulmonary Embolism Market Overview
• 24.2. USA Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pulmonary Embolism Market

• 25.1. Canada Pulmonary Embolism Market Overview
• 25.2. Canada Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pulmonary Embolism Market

• 26.1. South America Pulmonary Embolism Market Overview
• 26.2. South America Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pulmonary Embolism Market

• 27.1. Brazil Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pulmonary Embolism Market

• 28.1. Middle East Pulmonary Embolism Market Overview
• 28.2. Middle East Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pulmonary Embolism Market

• 29.1. Africa Pulmonary Embolism Market Overview
• 29.2. Africa Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pulmonary Embolism Market Competitive Landscape And Company Profiles

• 30.1. Pulmonary Embolism Market Competitive Landscape
• 30.2. Pulmonary Embolism Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck And Co.Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Pulmonary Embolism Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Sanofi S.A.
• 31.3. Bristol Myers Squibb Company
• 31.4. GSK plc
• 31.5. Abbott Laboratories
• 31.6. AstraZeneca plc
• 31.7. Medtronic plc
• 31.8. Eli Lilly and Company
• 31.9. Gilead Sciences Inc.
• 31.10. Baxter International Inc.
• 31.11. Teva Pharmaceutical Industries Ltd.
• 31.12. Regeneron Pharmaceuticals Inc.
• 31.13. Mylan N.V.
• 31.14. Daiichi Sankyo Co. Ltd.
• 31.15. Boehringer Ingelheim International GmbH

32. Global Pulmonary Embolism Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pulmonary Embolism Market

34. Recent Developments In The Pulmonary Embolism Market

35. Pulmonary Embolism Market High Potential Countries, Segments and Strategies

• 35.1 Pulmonary Embolism Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Pulmonary Embolism Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Pulmonary Embolism Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer